| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Jay S Skyler | Q64537724 |
| Kevan C Herold | Q87494800 | ||
| Jay M Sosenko | Q88890120 | ||
| Jerry P. Palmer | Q124249485 | ||
| P2093 | author name string | Type 1 Diabetes TrialNet and Diabetes Prevention Trial–Type 1 Study Groups | |
| P2860 | cites work | The PTPN22 1858T gene variant in type 1 diabetes is associated with reduced residual beta-cell function and worse metabolic control | Q46770114 |
| A risk score for type 1 diabetes derived from autoantibody-positive participants in the diabetes prevention trial-type 1. | Q46901921 | ||
| Insulin resistance and progression to type 1 diabetes in the European Nicotinamide Diabetes Intervention Trial (ENDIT). | Q46932751 | ||
| Patterns of metabolic progression to type 1 diabetes in the Diabetes Prevention Trial-Type 1. | Q46966748 | ||
| Models for predicting type 1 diabetes in siblings of affected children | Q46966752 | ||
| Genetic susceptibility markers in Danish patients with type 1 (insulin-dependent) diabetes--evidence for polygenicity in man. Danish Study Group of Diabetes in Childhood. | Q50556496 | ||
| Poor beta-cell function after the clinical manifestation of type 1 diabetes in children initially positive for islet cell specific autoantibodies. The Childhood Diabetes in Finland Study Group. | Q50946677 | ||
| Increasing the accuracy of oral glucose tolerance testing and extending its application to individuals with normal glucose tolerance for the prediction of type 1 diabetes: the Diabetes Prevention Trial-Type 1. | Q51482531 | ||
| Impaired glucose tolerance precedes but does not predict insulin-dependent diabetes mellitus: a study of identical twins. | Q51614900 | ||
| Natural course of insulin resistance in type I diabetes. | Q51633221 | ||
| Plasma insulin and growth hormone levels in obesity and diabetes | Q51691106 | ||
| Familial and sporadic insulin-dependent diabetes: evidence for heterogeneous etiologies? | Q67833760 | ||
| Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus | Q68134802 | ||
| Diagnosis of pre-type I diabetes | Q68205285 | ||
| Triad of markers for identifying children at high risk of developing insulin-dependent diabetes mellitus | Q69905447 | ||
| Ten-year prognosis of impaired glucose tolerance in siblings of patients with insulin-dependent diabetes | Q71470197 | ||
| Natural history of preclinical IDDM in high risk siblings. Childhood Diabetes in Finland Study Group | Q72134575 | ||
| Prognostic factors for the course of beta cell function in autoimmune diabetes | Q73336679 | ||
| Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. The Diabetes Control and Complications Trial Research Group | Q74366672 | ||
| Normal but increasing hemoglobin A1c levels predict progression from islet autoimmunity to overt type 1 diabetes: Diabetes Autoimmunity Study in the Young (DAISY) | Q79281970 | ||
| Role of insulin resistance in predicting progression to type 1 diabetes | Q80400738 | ||
| Validation of the Diabetes Prevention Trial-Type 1 Risk Score in the TrialNet Natural History Study | Q30502785 | ||
| Glucose excursions between states of glycemia with progression to type 1 diabetes in the diabetes prevention trial-type 1 (DPT-1). | Q30505367 | ||
| Trends of earlier and later responses of C-peptide to oral glucose challenges with progression to type 1 diabetes in diabetes prevention trial-type 1 participants | Q33683763 | ||
| Progression to diabetes in relatives of type 1 diabetic patients: mechanisms and mode of onset | Q33688616 | ||
| Type I (insulin dependent) diabetes: a disease of slow clinical onset? | Q34068531 | ||
| The Significance of Basal Insulin Levels in the Evaluation of the Insulin Response to Glucose in Diabetic and Nondiabetic Subjects* | Q34087250 | ||
| Insulin resistance in type 1 diabetes | Q34733637 | ||
| Pre-type 1 diabetes dysmetabolism: maximal sensitivity achieved with both oral and intravenous glucose tolerance testing | Q35792511 | ||
| Too much glucagon, too little insulin: time course of pancreatic islet dysfunction in new-onset type 1 diabetes | Q36756783 | ||
| Glucose and C-peptide changes in the perionset period of type 1 diabetes in the Diabetes Prevention Trial-Type 1. | Q36945228 | ||
| Diabetic subjects diagnosed through the Diabetes Prevention Trial-Type 1 (DPT-1) are often asymptomatic with normal A1C at diabetes onset | Q37163792 | ||
| Incident dysglycemia and progression to type 1 diabetes among participants in the Diabetes Prevention Trial-Type 1 | Q37319146 | ||
| Preservation of beta-cell function in autoantibody-positive youth with diabetes | Q37364982 | ||
| Predictive characteristics of diabetes-associated autoantibodies among children with HLA-conferred disease susceptibility in the general population | Q37429208 | ||
| Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus | Q40581531 | ||
| C-peptide in juvenile diabetics beyond the postinitial remission period. Relation to clinical manifestations at onset of diabetes, remission and diabetic control | Q41233625 | ||
| A randomized trial of intensive insulin therapy in newly diagnosed insulin-dependent diabetes mellitus | Q41291146 | ||
| Evidence for a long prediabetic period in type I (insulin-dependent) diabetes mellitus | Q41465592 | ||
| Temporary preservation of beta-cell function by diazoxide treatment in childhood type 1 diabetes | Q42466699 | ||
| Natural Course of Remission in IDDM During 1st yr After Diagnosis | Q42468184 | ||
| Predictive value of intravenous glucose tolerance test insulin secretion less than or greater than the first percentile in islet cell antibody positive relatives of type 1 (insulin-dependent) diabetic patients | Q42477104 | ||
| First-degree relatives of patients with type I diabetes mellitus. Islet-cell antibodies and abnormal insulin secretion | Q43744706 | ||
| Effects of insulin in relatives of patients with type 1 diabetes mellitus | Q44010590 | ||
| Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial | Q44333576 | ||
| Insulin secretion in type 1 diabetes | Q44745157 | ||
| European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes | Q44814113 | ||
| B-cell function and blood glucose control in insulin dependent diabetics within the first month of insulin treatment | Q45038352 | ||
| Insulin resistance is a risk factor for progression to type 1 diabetes | Q45103752 | ||
| Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial--Type 1. | Q46458859 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial-NoDerivatives | Q6937225 |
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | glucose | Q37525 |
| type-1 diabetes | Q124407 | ||
| glycobiology | Q899224 | ||
| disease progression | Q86758334 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 1331-1337 | |
| P577 | publication date | 2012-06-01 | |
| P1433 | published in | Diabetes | Q895262 |
| P1476 | title | The metabolic progression to type 1 diabetes as indicated by serial oral glucose tolerance testing in the Diabetes Prevention Trial-type 1. | |
| P478 | volume | 61 |
| Q36895385 | Antidiabetic and antioxidant effects of catalpol extracted from Rehmannia glutinosa (Di Huang) on rat diabetes induced by streptozotocin and high-fat, high-sugar feed |
| Q92495208 | Associations of HbA1c with the timing of C-peptide responses during the oral glucose tolerance test at the diagnosis of type 1 diabetes |
| Q89999336 | Cause or effect? A review of clinical data demonstrating beta cell dysfunction prior to the clinical onset of type 1 diabetes |
| Q38895409 | Dysregulation of glucose metabolism in preclinical type 1 diabetes |
| Q33854613 | Early prediction of autoimmune (type 1) diabetes |
| Q37333539 | Following the fate of the failing β-cell: new insights from first-phase insulin responses |
| Q44972607 | Glucose tolerance and beta-cell function in islet autoantibody-positive children recruited to a secondary prevention study |
| Q38991217 | Increase in Pancreatic Proinsulin and Preservation of β-Cell Mass in Autoantibody-Positive Donors Prior to Type 1 Diabetes Onset |
| Q36995568 | Life and death of β cells in Type 1 diabetes: A comprehensive review |
| Q26864403 | Lost in translation: endoplasmic reticulum stress and the decline of β-cell health in diabetes mellitus |
| Q92716793 | Low Grade Islet but Marked Exocrine Pancreas Inflammation in an Adult with Autoimmune Pre-Diabetes |
| Q51302837 | OGTT and random plasma glucose in the prediction of type 1 diabetes and time to diagnosis. |
| Q51319342 | Postoperative impaired glucose tolerance is an early predictor of pancreas graft failure. |
| Q50066962 | Predicting progression to diabetes in islet autoantibody positive children |
| Q38161556 | Predictors of progression to Type 1 diabetes: preparing for immune interventions in the preclinical disease phase |
| Q49110588 | Relationship between glycaemic variability and hyperglycaemic clamp-derived functional variables in (impending) type 1 diabetes. |
| Q38692770 | Revisiting multiple models of progression of β-cell loss of function in type 1 diabetes: Significance for prevention and cure |
| Q37659402 | Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association |
| Q34983677 | Testing agents for prevention or reversal of type 1 diabetes in rodents |
| Q93109000 | The effect of type 1 diabetes on the developing brain |
| Q49691828 | The shape of the glucose concentration curve during an oral glucose tolerance test predicts risk for type 1 diabetes |
| Q38607498 | Towards an Earlier and Timely Diagnosis of Type 1 Diabetes: Is it Time to Change Criteria to Define Disease Onset? |
| Q35183950 | β cell death and dysfunction during type 1 diabetes development in at-risk individuals |
Search more.